Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Sep;11(3):362-4.
doi: 10.1016/j.clgc.2013.01.003. Epub 2013 Jun 20.

Dramatic and prolonged PSA response after retreatment with a PSA vaccine

Adam Rojan  1 , Renee Funches, Meredith M Regan, James L Gulley, Glenn J Bubley
Affiliations
Case Reports

Dramatic and prolonged PSA response after retreatment with a PSA vaccine

Adam Rojan et al. Clin Genitourin Cancer. 2013 Sep.
No abstract available

Keywords: Immunologic response; PROSTVAC-VF; Revaccination.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors have stated that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Prostate-Specific Antigen (PSA) Values (y-Axis) are in Nanograms/Milliliter (ng/mL), Plotted on the Natural Log Scale; PSA was Measured at 2 Different institutions as Denoted by the 2 Colors. Time (x-Axis) is in Years Relative to Prostatectomy in 1993. The Solid Black Line is a Cubic Spline Smooth. The Dashed Blue Lines are the Linear Segments Fit Using Segmented Linear Regression Modeling to Estimate PSA Level Doubling Time During Different Periods. Annotated Peak and Nadir PSAs and Linear Segments of the Model are Summarized in Table 1 Abbreviation: XRT = Radiation Therapy.
See this image and copyright information in PMC

References

    1. Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther 2012; 12:463–78. - PMC - PubMed
    1. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099–105. - PMC - PubMed
    1. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122–32. - PubMed
    1. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591–7. - PubMed
    1. Vergati M, Cereda V, Madan RA, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 2011; 60:197–206. - PMC - PubMed

Publication types